Add to ORKG32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- SEP 14-17, 2016 -- London, ENGLANDWOS: 000383267201390…European Comm Treatment & Res Multiple Sclerosi
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) /...
To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NED...
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI out...
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Abstract Background Evidence on the use of fingolimod in real-world clinical practice and data on pa...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
Supplemental material for Real-world experience of fingolimod in patients with multiple sclerosis (M...
Online ahead of printInternational audienceIntroduction: It is important to confirm the effectivenes...
Charlotte Druart, Souraya El Sankari, Vincent van Pesch Neurology Department, Cliniques Univers...
The objective of this study was to characterize the demographic and clinical profile of RRMS patient...
Objective. The aim of this prospective observational multicenter postmarketing study was to evaluate...
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Com...
With a growing number of disease-modifying therapies becoming available for relapsing multiple scler...
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) /...
To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NED...
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI out...
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -...
Abstract Background Evidence on the use of fingolimod in real-world clinical practice and data on pa...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
Supplemental material for Real-world experience of fingolimod in patients with multiple sclerosis (M...
Online ahead of printInternational audienceIntroduction: It is important to confirm the effectivenes...
Charlotte Druart, Souraya El Sankari, Vincent van Pesch Neurology Department, Cliniques Univers...
The objective of this study was to characterize the demographic and clinical profile of RRMS patient...
Objective. The aim of this prospective observational multicenter postmarketing study was to evaluate...
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Com...
With a growing number of disease-modifying therapies becoming available for relapsing multiple scler...
35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) /...
To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NED...
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI out...